Prenetics, a health-tech and longevity company, is shifting its strategic focus entirely towards its consumer wellness brand, IM8, co-founded with David Beckham. This move signals a departure from the company's previous dual-engine strategy, which included a significant investment in Bitcoin as a corporate treasury asset.
In June 2025, Prenetics became the first health company to announce a public Bitcoin treasury strategy, initially purchasing $20 million worth of Bitcoin. The company expanded its Bitcoin holdings, aiming for $1 billion in Bitcoin holdings within five years, alongside $1 billion in annual revenue. By late October 2025, Prenetics held approximately 275 BTC, valued at $31 million. On October 31, 2025, Prenetics announced the acquisition of an additional 100 BTC at approximately $109,594 per bitcoin, bringing their total holdings to 378 BTC, worth around $41 million. As of November 24, 2025, the company's Bitcoin holdings had reached 501 BTC.
However, the company is now prioritizing the growth of IM8, a premium supplement brand that has seen rapid success. IM8 achieved $50 million ARR in six months and partners with elite athletes like Aryna Sabalenka. By late October 2025, IM8 had reached $100 million in annual recurring revenue in just 11 months from launch. Financial year 2026 revenue guidance projects IM8 will generate $180-$200 million.
The decision to focus on IM8 comes as the global health and wellness market continues to expand. Prenetics aims to capitalize on the demand for personalized wellness solutions through its collaboration with David Beckham and a team of scientists. Beckham's involvement and focus on advanced consumer health products have been key to IM8's growth.
While Prenetics embraced Bitcoin as a way to hedge against currency volatility and appeal to investors interested in digital assets, the company will now concentrate its resources on strengthening its position in the competitive health supplement market. The shift allows Prenetics to channel funds towards research and development in personalized nutrition and expand IM8's global distribution.
Despite the change in strategy, Prenetics leadership remains optimistic about the company's future. In November 2025, key members of the executive leadership team purchased shares of Prenetics' common stock, demonstrating confidence in the long-term vision of Prenetics and IM8. CEO Danny Yeung stated that IM8 is scaling rapidly as one of the fastest-growing wellness brands globally, reinforcing long-term financial resilience.
